ClinicalTrials.gg
RecruitingNCT04610476Updated Nov 14, 2022

Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

A Phase 3 interventional study of Prednisolone and Sulfasalazine in Psoriatic Arthritis, Withdrawal and Reduction, sponsored by University of Erlangen-Nürnberg Medical School. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-14.

Sponsored by University of Erlangen-Nürnberg Medical School · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Oct 2020; still recruiting 6 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 109 studies in Arthritis, Psoriatic with a site in Germany — 10 open to participants now, 28 under way, 18 of them phase 3. Arthritis, Psoriatic · Germany.

Planned enrollment
53rd of 90
270 · median 357
Started
2020
with 6 others
Phase 3
56 of 109
4 open now
Primary completion
2024-10
later than 2 of 27 live
Registered
73rd of 109
by date
Lead sponsor
4 of 109
University of Erlangen-Nürnberg Medical School

Among the 109 studies in Arthritis, Psoriatic with a site in Germany, this one is the 53rd largest by planned enrollment of the 90 interventional ones that give a count, is one of 7 that started in 2020, is one of 56 in phase 3, reaches primary completion later than 2 of the 27 other live ones, and was the 73rd registered.

Arthritis, Psoriatic

602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

10 of the 109 studies in Arthritis, Psoriatic with a site in Germany are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 109 studies in Arthritis, Psoriatic with a site in Germany, or all of them as a file.
02

Study summary

The rationale for this study is to investigate whether in psoriatic arthritis (PsA) patients in stable remission a reduction or complete discontinuation of immunosuppressive therapy can be achieved in a treat-to-target approach while maintaining in remission. Due to the lack of reliable data that answers the question of how to safely reduce medication in which patients, this study will test a pragmatic treatment algorithm that can be applied in clinical practice and that offers a gradual reduction with escape strategies in order to facilitate the maintenance of remission.

03

Conditions studied

  • Psoriatic Arthritis
  • Withdrawal
  • Reduction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained from the subject
  • Understanding of study procedures and willingness to abide by all procedures during the course of the study.
  • Adult subject; age range 18-≤75 years
  • Male or female subject
  • Diagnosis of PsA according to CASPAR criteria
  • Disease status "MDA" for at least 6 months
  • Subject should have been treated without alterations of therapy (fixed dose and drug) for at least 6 months with one or more of the following drugs:

    i. csDMARD Leflunomid (e.g. Arava), Sulfasalazin (e.g. Azulfidine RA, Pleon RA), Methotrexate (e.g. Lantarel, Metex) AND/OR ii. bDMARD/tsDMARD: Etanercept (e.g. Enbrel, Erelzi, Benepali), Adalimumab (e.g. Humira, Amgevita, Imraldi, Hyrimoz), Infliximab (e.g. Remicade, Zessly, Inflectra), Golimumab (Simponi), Certolizumab (Cimzia), Abatacept (Orencia), Apremilast (Otezla), Ustekinumab (Stelara), Secukinumab (Cosentyx), Ixekizumab (Taltz), Tofacitinib (Xeljanz) AND/OR (c) (≤5mg prednisolone equivalent).

  • Women of must be using a highly effective method of .
  • Male subjects using an adequate contraceptive method at the investigator's discretion.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of any other rheumatological/ immunological disease such as rheumatoid arthritis, SLE, PSS, MCTD, M. Behcet or M. Wegener
  • Concomitant florid (not sufficiently adjusted under treatment) disease such as autoimmune hepatitis or Hashimoto's disease
  • Use of any inadmissible medication (e.g. current treatment with DMARDs other than mentioned above or drugs under development)
  • Treatment with systemic (daily dose >5mg prednisolone equivalent) during the last 6 months before randomization. Intra-articular or entheseal injections of glucocorticoids do not constitute an exclusion criterion
  • Malignant disease currently under oncological treatment or history of a recent with moderate or high risk of relapse within 5 years prior to Screening
  • Existence of another disease including the presence of laboratory abnormalities which, at the discretion of the investigator, would result in a disproportionate risk to the patient concerned or confounds the ability to interpret data from the study
  • Any anti-inflammatory (excluding NSAIDs) or therapy for other reasons than PsA or psoriasis during the last 3 months before Screening
  • Nursing mother or pregnant woman as verified by a positive pregnancy test
  • Known to the IMPs or any of their formulation ingredients
  • Subject who is imprisoned or is lawfully kept in an Institution
  • Employee or direct relative of an employee of the study site or the Sponsor
  • Participation in an interventional clinical study with an IMP within the last 4 weeks before Screening
  • Previous participation in this clinical study
  • Planned extended stay outside the region which prevents compliance with the visit schedule
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
270 participants (estimated)

Study arms

  • No intervention
    Control group

    Individual previous stable glucocorticoid/DMARD therapy is continued

  • Experimental
    Reduction group

    Individual previous stable dosage of glucocorticoids/DMARDs will be stepwise reduced according to a predefined algorithm

    Drug: Prednisolone · Drug: Sulfasalazine · Drug: Leflunomide · Drug: Methotrexate · Drug: Tofacitinib · Drug: Apremilast · Drug: Etanercept · Drug: Adalimumab · Drug: Infliximab · Drug: Certolizumab pegol · Drug: Golimumab · Drug: Abatacept · Drug: Secukinumab · Drug: Ixekizumab · Drug: Ustekinumab

Interventions

  • Prednisolone oral 1-5 mg/day

    Also known as: Prednisolone generic drugs

  • Sulfasalazine oral 2 x 1000 mg/day

    Also known as: Azulfidine

  • Leflunomide oral 20 mg/day

    Also known as: Arava

  • Methotrexate oral \> 10 - 30 mg/ week/ 10 mg/week/ 7.5 mg/week; s.c. 15 (7.5 -25) mg/week

    Also known as: Lantarel, Metex

  • Tofacitinib oral 2 x 5 mg/day/ 1 x 5 mg/day/11 mg/day

    Also known as: Xeljanz

  • Apremilast oral 2 x 30 mg/day/1 x 30 mg/day

    Also known as: Otezla

  • Etanercept s.c. 2 x 25 mg /week OR 1 x 50 mg/week

    Also known as: Enbrel, Erelzi, Benepali

  • Adalimumab s.c. 40 mg every 2 weeks

    Also known as: Humira, Amgevita, Imraldi, Hyrimoz

  • Infliximab i.v. 5 mg/kg BW every 8 weeks

    Also known as: Remicade, Zessly, Inflectra

  • Certolizumab pegol s.c. 1x 200 mg every 2 weeks/1x400 mg every 4 weeks

    Also known as: Cimzia

  • Golimumab s.c. 1x 50 mg every 4 weeks

    Also known as: Simponi

  • Abatacept s.c. 1x125 mg/week OR Abatacept i.v. 500-1000mg (adapted to BW) every 4 weeks

    Also known as: Orencia

  • Secukinumab s.c.1x 150 mg OR 1x 300 mg every 4 weeks

    Also known as: Cosentyx

  • Ixekizumab s.c. 1x 80 mg every 4 weeks

    Also known as: Taltz

  • Ustekinumab s.c. Maintenance dose 1x45 mg every 12 weeks

    Also known as: Stelara

06

What researchers measure

Primary outcomes

  1. Presence of MDA (minimal disease activity) 12 months after baseline.

    The MDA status comprises the assessment of different domains of PsA, consisting of the following individual components: * swollen and tender joint count * tender entheseal point count * skin involvement (PASI)patient self-assessment of pain (VAS) * global disease activity status * subject's self-assessment of functional ability using Stanford Health Assessment Questionnaire disability index, (HAQ-DI) MDA is defined as the presence of 5 of the following 7 criteria: 1. tender joint count ≤1 2. swollen joint count ≤1 3. tender entheseal point count ≤1 (means: remission) 4. PASI ≤1 OR body surface area (BSA) ≤3% 5. patient pain VAS ≤15 6. patient global activity VAS ≤20 7. HAQ-DI ≤0.5

    Time frame: 12 months

Secondary outcomes

  1. Key secondary endpoint: PASDAS (Psoriatic Arthritis Disease Activity Score)

    The PASDAS is a composite disease activity index (range 0-10) for psoriatic arthritis (PsA) incorporating seven domains: patient and physician global activity VAS scores, tender and swollen joint counts (arthritis), dactylitis, enthesitis (Leeds), health-related QoL (SF-36), and CRP level. PASDAS has demonstrated to have a better discriminate capacity in distinguishing high and low disease activity. The PASDAS is computed by the following equation: PASDAS = (((0, 18 ∗ ∗√(PhGA) + 0.159 ∗ ∗√(PtGA) - 0.253 ∗ ∗√(SF36 -PCS) + 0.101 ∗ lognat(SJC66 + 1)) + 0.048 ∗ lognat(SJC68 +1)) + 0.23 ∗ lognat (Leeds enthesitis index + 1)) + 0.37 ∗lognat (tender dactylitis count + 1) + 0.102 ∗ lognat (CRP +1) + 2 ∗ 1.5.

    Time frame: 12 months

  2. Key secondary endpoint: DAPSA (Disease Activity in PSoriatic Arthritis)

    The DAPSA score determines changes in the disease activity of subjects diagnosed with PsA. DAPSA is a composite score which is calculated from the sum of: number of tender joints (0-68), number of swollen joints (0-66, hips are not taken into account), CRP (mg/dl), subject's assessment of global status of disease activity using VAS (0-10) and patient's self-assessment of pain using VAS (0-10). A value of the composite score DAPSA 0-≤ 4 marks remission, 5-14 marks low, 15-28 moderate and \>28 high disease activity

    Time frame: 12 months

  3. Key secondary endpoint: CPDAI (Composite Psoriatic Disease Activity Index)

    The composite psoriatic disease activity index (CPDAI) assesses disease activity under five domains using well established and validated instruments of PsA disease documentation as proposed by GRAPPA. The domains and the respective instrument are as follows: joint disease (SJC/TJC, HAQ), skin involvement (PASI, DLQI), enthesitis (LEI, HAQ), dactylitis (dactylitis digit count, HAQ) and spinal involvement (BASDAI and ASQoL). Using the instruments and ranges of values, disease activity under each domain is graded as none (0) -mild (1) -moderate (2) and severe (3) giving a range attainable CPDAI scores of between 0 and 15. The CPDAI correlates well with patient and physician global disease activity assessments and is an effective tool that clearly distinguishes those who require a treatment change from those who do not.

    Time frame: 12 months

  4. Number of swollen and tender joints

    An assessment of 66 joints for swelling and 68 joints for tenderness will be made (including the DIP joints of the hands and excluding hips for swelling).

    Time frame: 12 months

  5. Number of tender entheseal points: SPARCC (Spondyloarthritis Consortium of Canada)

    The SPARCC enthesitis score is based on the counting of the presence or absence of tenderness on 16 entheseal sites (eight sites on each body side, respectively): lateral epicondyle, medial epicondyle, supraspinatus insertion into greater tuberosity of humerus, greater trochanter, quadriceps insertion into superior borders of patella, patellar ligament insertion into inferior pole of patella or tibial tubercle, Achilles tendon insertion into calcaneum, and plantar fascia insertion into calcaneum. Tenderness on examination is recorded as either present (1) or absent (0) for each of the 16 sites, summarized in an overall score ranging from 0 to 16. A higher count represents a greater enthesitis burden

    Time frame: 12 months

  6. Number of tender entheseal Points: LEI (Leeds Enthesitis Index)

    The LEI includes 3 entheseal sites on each body side, respectively: lateral epicondyles, medial condyles of the femur, and Achilles tendons. Tenderness on examination is recorded as either present (1) or absent (0) for each of the 6 sites, for in an overall score ranging from 0 to 6. A higher count represents a greater enthesitis burden

    Time frame: 12 months

  7. Number of tender entheseal Points: MASES (Maastricht Ankylosing Spondylitis Enthesitis Score)

    The MASES includes 6 entheseal sites on each body side (first costochondral joints, seventh costochondral joints, posterior superior iliac spines, anterior superior iliac spines, iliac crests, proximal insertion of Achilles tendons) and in addition the fifth lumbar spinous process. Tenderness on examination is recorded as either present (1) or absent (0) for each of the 13 sites, for an overall score ranging from 0 to 13. A higher count represents a greater enthesitis burden

    Time frame: 12 months

  8. Dactylitis counts

    The presence of dactylitis will be assessed by counting the fingers/toes with dactylitis.

    Time frame: 12 months

  9. Activity of psoriasis: PASI (Psoriasis Area and Severity Index)

    PASI combines the assessment of the severity of lesions and the area affected into a single score ranging from 0 (no disease) to 72 (maximal disease).

    Time frame: 12 months

  10. Activity of psoriasis: BSA (body surface area)

    For the BSA assessment of psoriatic skin involvement the size of the subject's hand is used as a scale to estimate the size of the skin surface covered by psoriasis. The subject's palm covers roughly 1% of body's surface area. An involved area of \<3% of the skin is considered as mild, of 3 10% as moderate, and \>10% as severe psoriasis

    Time frame: 12 months

  11. Activity of axial Involvement: BASDAI (Disease Activity of Ankylosing Spondylitis)

    The BASDAI consists of a one through 10 scale (one being no problem and 10 being the worst problem) which is used to answer 6 questions pertaining to the 5 major symptoms of AS: Fatigue, Spinal pain, Joint pain / swelling, areas of localized tenderness (also called enthesitis, or inflammation of tendons and ligaments), morning stiffness duration, morning stiffness severity. To give each symptom equal weighting, the mean (average) of the two scores relating to morning stiffness is taken. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score. Scores of 4 or greater suggest suboptimal control of disease, and patients with scores of 4 or greater are usually good candidates for either a change in their medical therapy or for enrollment in clinical trials evaluating new drug therapies directed at Ankylosing Spondylitis

    Time frame: 12 months

  12. Quality of life and health/disability: PsAID-12 (Psoriatic Arthritis Impact of Disease)

    The PsAID-12 is a score based on a subject's self-assessment questionnaire and used to measure the impact of psoriatic arthritis on a person's life. The questionnaire comprises 12 numeric rating scale questions covering the following topics: pain, fatigue, skin problems, work/leisure activities, functional capacity, discomfort, sleep disturbance, coping with PsA, anxiety and fear and uncertainty, embarrassment and/or shame, social participation, depression. Each question receives a score from 0 to 10. For evaluation these are weighted by factors and then summarized. The range of the final PsAID-score will be 0-10 where higher figures indicate worse status.

    Time frame: 12 months

  13. Quality of life and health/disability: HAQ-DI (Stanford Health Assessment Questionnaire Disability Index)

    The Stanford Health Assessment Questionnaire is based on a subject's self-assessment questionnaire for persons diagnosed with PsA. The HAQ-DI assesses a patient's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities. There are 20 questions in eight categories of functioning which represent a comprehensive set of functional activities - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The stem of each item asks for the past week "Are you able to ..." perform a particular task. The patient's responses are made on a scale from zero (no disability) to three (completely disabled). Each category contains at least two specific component questions.

    Time frame: 12 months

  14. Quality of life and health/disability: DLQI (Dermatology Life Quality Index)

    The DLQI is a score based on a subject's self-assessment questionnaire and used to measure the impact of the skin disease (psoriasis) on the quality of life of an affected person. The questionnaire contains 10 questions covering the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, and treatment. Each question refers to the impact of the skin disease on the patient's life over the previous week. Each question receives a score from 0 to 3. These are summarized to a final score with a possible range from 0 (meaning no impact on quality of life) to 30 (meaning maximum impact on quality of life).

    Time frame: 12 months

  15. Quality of life and health/disability: ASQoL (Ankylosing Spondylitis Quality of Life)

    The ASQoL is a scale based on a subject's self-assessment questionnaire to measure the impact of ankylosing spondylitis (AS) on the quality of life of a diseased person with emphasis on the ability of the person to fulfill his or her needs. It consists of 18 items requesting a yes or no response to questions related to the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. The score range is 0-18. High scores indicate worse quality of life.

    Time frame: 12 months

  16. Quality of life and health/Disability: SF-36 (Short Form Health)

    SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. These measures rely upon patient self-reporting and are now widely utilized for routine monitoring and assessment of care outcomes in adult patients. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. The eight sections are: vitality, physical functioning, bodily pains, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    Time frame: 12 months

  17. Pain (VAS)

    The subject will be asked to place a vertical line on a 100-mm scale on which the left-hand boundary represents "no pain," and the right-hand boundary represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary will be recorded

    Time frame: 12 months

  18. Proportion of patients with loss of MDA within 12 months after baseline

    Time frame: 12 months

  19. Proportion of patients with loss of MDA within 24 months after baseline

    Time frame: 24 months

  20. Time to loss of MDA

    Time frame: 12 months

  21. Time needed to restore MDA after readjustment of the DMARD therapy in subjects who lost MDA within the intervention period

    Time \[days/weeks/month\] to restore after lost MDA

    Time frame: 12 months

  22. Biomarker levels

    Serum cytokines, and molecular characterization of peripheral blood cells (e.g. IL-8 (CXCL8), Calprotectin (S100A9/S100A9). IL-22, lipocalin-2 (NGAL), beta defensin 2 \[11\], ILC, PBMC)

    Time frame: 24 months

  23. Intervention-related events within the observation period of 24 months after baseline

    Observed symptoms (AE) related to reduction (intervention) such as symptoms suspicious of worsening disease activity (flare)

    Time frame: 24 months

  24. AE (Adverse Event)

    Adverse Event

    Time frame: 12 months

  25. AR (Adverse Reaction)

    Adverse Reaction

    Time frame: 12 months

  26. SAE (Serious Adverse Event)

    Serious Adverse Event

    Time frame: 12 months

  27. SAR (Serious Adverse Reaction)

    Serious Adverse Reaction

    Time frame: 12 months

  28. SUSAR (Suspected Unexpected Serious Adverse Reaction)

    Suspected Unexpected Serious Adverse Reaction

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — After all data of the trial were published by the study group, the data might be provided to interested scientists on request (e.g. for meta-analyses, health related registers or other scientific questions) in an anonymized way, if the members of the study group agree.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Oct 2024, 48 months after the start.

Of 74 phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 42. This study's planned 48 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2020
First posted
Oct 30, 2020
StartActual
Oct 19, 2020
Primary completionEst.
Oct 19, 2024
CompletionEst.
Oct 19, 2025
Last update
Nov 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04610476
Responsible party
Sponsor
First posted
Oct 30, 2020
Start date
Oct 19, 2020
Primary completion
Oct 19, 2024 (estimated)
Completion
Oct 19, 2025 (estimated)
Last update
Nov 14, 2022

Study contacts

David Simon, MD
Contact
david.simon@uk-erlangen.de
+4991318532093
Arnd Kleyer, MD
Contact
arnd.kleyer@uk-erlangen.de
+4991318532093

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Prednisolone · Sulfasalazine · Leflunomide · Methotrexate · Tofacitinib · Apremilast · Etanercept · Adalimumab · Infliximab · Certolizumab Pegol · Golimumab · Abatacept · Secukinumab · Ixekizumab · Ustekinumab

Start the discussion